Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ESMO 2018 /
Results from the SOLAR-1 trial for advanced breast cancer

19th - 23rd Oct 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 20.10.18
Views: 1021

Prof Fabrice André - Institut Gustave Roussy, Paris, France

Prof Fabrice André speaks with ecancer at ESMO 2018 in Munich about results from a trial to treat advanced breast cancer with fulvestrant and targeted PI3Ka inhibitor alpelisib.

He describes how alpelisib differs from other PI3K inhibitors as it selectively targets the alpha isoform, allowing the enzyme to continue to function in other tissues.

Prof André details the improved PFS seen in the trial, with adverse events of rash and hyperglycaemia being common but manageable.

For more on these results, watch his presentation of the data at a conference session here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation